Who is sponsoring NCT02586883?

NCT02586883 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02586883?

Interventions in NCT02586883: bronchial ddp test.

What condition does NCT02586883 study?

NCT02586883 studies Idiopathic Dilation of the Bronchi.

Is NCT02586883 still recruiting?

NCT02586883 is currently completed. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT02586883: EPITRANS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi

Completed NA Last updated 30 March 2026

What this trial tests

NA trial testing bronchial ddp test in Idiopathic Dilation of the Bronchi in 42 participants. Completed in 23 November 2020.

Timeline

29 March 2016

Primary endpoint
23 November 2020

23 November 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	42
Start date	29 March 2016
Primary completion	23 November 2020
Estimated completion	23 November 2020
Sites	1 location across France

Drugs / interventions tested

bronchial ddp test

Conditions studied

Idiopathic Dilation of the Bronchi — all drugs for Idiopathic Dilation of the Bronchi →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 2 to 20, any sex, with Idiopathic Dilation of the Bronchi. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify the abnormalities of bronchial trans-epithelial transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the bronchi.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02586883 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02586883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing